Back to top

Image: Bigstock

Gilead Buys Kite, the Future of CAR-T, and A Visit to the New Whole Foods

Read MoreHide Full Article

  • (0:35) - Hurricane Harvey and North Korea Tensions
  • (2:30) - Gilead's Acquisition of Kite Pharma: What Is CAR-T Therapy?
  • (4:45) - Novartis CAR-T Cell Therapy Receives Approval By FDA
  • (6:50) - CAR-T Biotech Stocks On The Rise
  • (10:40) - Is This A New Era For Biotech?
  • (15:15) - Price Cutting On Whole Foods Products
  • (19:20) - Amazon Echoes and Instacart Indirect Competition
  • (23:45) - Upcoming Rewards Program For Prime Members
  • (26:00) - Episode Roundup:

On today’s episode of the Zacks Friday Finish Line, Content Writer Ryan McQueeney and Editor Maddy Johnson take on this week’s biggest stories, including Gilead’s acquisition of Kite Pharma, the future of the CAR-T therapy industry, and Amazon’s changes to Whole Foods stores.

Make sure to subscribe and leave the show a rating on iTunes!

It was a busy week in the biotech sector, so Maddy and Ryan welcomed an expert guest, Brad Loncar, to recap the latest major events. Brad is the creator of the Loncar Cancer Immunotherapy Index, which tracks the combined performance of several major companies that are developing therapies to treat cancer by harnessing the body’s own immune system.

This makes Brad the perfect person to discuss the Gilead’s (GILD - Free Report) massive $11.9 billion takeover of Kite Pharma KITE, as well as the milestone of Novartis’ NVS CAR-T cancer therapy. Maddy and Ryan also asked Brad about the impact that these events have had on other CAR-T develops, such as Juno Therapeutics JUNO and Bluebird Bio BLUE, and Brad shared some key info that every bio tech investor needs to know right now.

Finally, Maddy and Ryan also discussed their recent trip to a Whole Foods WFM store to investigate the changes made by Amazon AMZN this week. Make sure to tune in to the show to hear their reactions, and check out some pictures from the visit below:



As a reminder, if you feel that we missed something, or if you want us to cover a different story, shoot us an email at Make sure to check out all of our other audio content at, and remember to subscribe and leave us a rating on iTunes.

As always, thanks for listening to this episode of the Zacks Friday Finish Line, and check back for even more news from the investment and financial world!

Want more stock market analysis from this author? Make sure to follow @Ryan_McQueeney on Twitter!

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Gilead Sciences, Inc. (GILD) - free report >>